Hypertension or high blood pressure is now a common disease in the community. Quite often the sufferer does not realize it because the disease has no specific symptoms and come tibat unexpectedly. And if not handled properly, hypertension major risk to sufferers die from cardiovascular complications such as stroke, heart or kidney failure.
The high rates of hypertension epidemiology in the world, has prompted numerous studies aimed to reduce morbidity and mortality from this disease. The study not only aimed at controlling blood pressure, but also to protect vital organs from damage caused by hypertension.
Including the results of studies ONTARGET (Ongoing telmisartan Alone and in combination with Ramipril Global Endpoint Trial). These studies do clinical testing is random, double-blind who evaluated more than 25,260 patients at high risk of cardiovascular disease. ONTARGET is not a hypertension study, because patients with blood pressure> 160/100 mm Hg is not included, but included patients with normal blood pressure and controlled.
Studies that have been evaluated by the Boehringer Ingelheim conducted in nine Asian countries, China, Taiwan, Thailand, Singapore, Malaysia, Philippines, India, Japan and Korea in 2001, has reported results on March 31, 2008. Proving, if telmisartan, an anti-hypertensive drug classes Angiotensin II Receptor Blocker (ARB) modern. Which can provide protection equivalent to ramipril, which is the golden standard of treatment of hypertension. And telmisartan may reduce the risk of death from cardiovascular disease.
dr. Ann Arieska Soenarta, SpJP (K), as Chairman of the Hypertension Society of Indonesia said that, if cardiovascular disease is a term for disorders that cause heart disease and blood vessels. Which can lead to heart attacks, strokes, chest pain (angina), temporary damage to vision, speech, sensation of movement (mini stroke or transient ischemic attack). Until morbidity or spastic arm and leg (caludication), and the disease causes death or disability in seconds.
"Every two seconds, one person died of cardiovascular disease," said dr. Ann-familiar call, while giving an explanation of the importance of ONTARGET study, at the Hotel Mulia, Jakarta.
The doctor who is also a cardiologist at the Harapan Kita Hospital, Jakarta said, if the primary cause of cardiovascular death and disability worldwide. Approximately 17.5 million people died of cardiovascular disease in 2005. Among the 17.5 million it recorded 7.6 million due to coronary heart disease and 5.7 million due to stroke. And hypertension is a risk factor for most causes of morbidity and mortality due to cardiovascular disease.
Factors that can be controlled for cardiovascular: - High cholesterol levels in the blood - Hypertension - Diabetes mellitus - Obesity - Lifestyle inactivity, smoking, excessive alcohol consumption
Factors that can not be controlled: - Age - Gender - Medical history on the family kardivaskular
The high rates of hypertension epidemiology in the world, has prompted numerous studies aimed to reduce morbidity and mortality from this disease. The study not only aimed at controlling blood pressure, but also to protect vital organs from damage caused by hypertension.
Including the results of studies ONTARGET (Ongoing telmisartan Alone and in combination with Ramipril Global Endpoint Trial). These studies do clinical testing is random, double-blind who evaluated more than 25,260 patients at high risk of cardiovascular disease. ONTARGET is not a hypertension study, because patients with blood pressure> 160/100 mm Hg is not included, but included patients with normal blood pressure and controlled.
Studies that have been evaluated by the Boehringer Ingelheim conducted in nine Asian countries, China, Taiwan, Thailand, Singapore, Malaysia, Philippines, India, Japan and Korea in 2001, has reported results on March 31, 2008. Proving, if telmisartan, an anti-hypertensive drug classes Angiotensin II Receptor Blocker (ARB) modern. Which can provide protection equivalent to ramipril, which is the golden standard of treatment of hypertension. And telmisartan may reduce the risk of death from cardiovascular disease.
dr. Ann Arieska Soenarta, SpJP (K), as Chairman of the Hypertension Society of Indonesia said that, if cardiovascular disease is a term for disorders that cause heart disease and blood vessels. Which can lead to heart attacks, strokes, chest pain (angina), temporary damage to vision, speech, sensation of movement (mini stroke or transient ischemic attack). Until morbidity or spastic arm and leg (caludication), and the disease causes death or disability in seconds.
"Every two seconds, one person died of cardiovascular disease," said dr. Ann-familiar call, while giving an explanation of the importance of ONTARGET study, at the Hotel Mulia, Jakarta.
The doctor who is also a cardiologist at the Harapan Kita Hospital, Jakarta said, if the primary cause of cardiovascular death and disability worldwide. Approximately 17.5 million people died of cardiovascular disease in 2005. Among the 17.5 million it recorded 7.6 million due to coronary heart disease and 5.7 million due to stroke. And hypertension is a risk factor for most causes of morbidity and mortality due to cardiovascular disease.
Factors that can be controlled for cardiovascular: - High cholesterol levels in the blood - Hypertension - Diabetes mellitus - Obesity - Lifestyle inactivity, smoking, excessive alcohol consumption
Factors that can not be controlled: - Age - Gender - Medical history on the family kardivaskular
Anda sedang membaca artikel tentang
Hypertension, Beware!
Dengan url
http://hypertensionpreventionsolutions.blogspot.com/2011/06/hypertension-beware.html
Anda boleh menyebar luaskannya atau mengcopy paste-nya
Hypertension, Beware!
namun jangan lupa untuk meletakkan link
sebagai sumbernya
0 komentar:
Posting Komentar